A Phase 1, Open-Label, Single-Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment.

Trial Profile

A Phase 1, Open-Label, Single-Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Lorcaserin (Primary)
  • Indications Obesity
  • Focus Pharmacokinetics
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 29 Mar 2017 Results assessing pharmacokinetics and tolerability of Lorcaserin in different populations in three studies (NCT00828581, NCT00828438, and NCT00828932) published in the Clinical Therapeutics
    • 30 Jul 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
    • 30 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top